Our Faculty

Alexander T Pearson, MD PhD

  • Associate Professor of Medicine
    Committee on Cancer Biology
    Committee on Clinical Pharmacology and Pharmacogenomics
    Committee on Genetics, Genomics and Systems Biology
  • Clinical Interests: Clinical Trials, Immunotherapy, Medical education, Salivary gland cancers, Squamous Cell Carcinoma Tumors
  • Research and Scholarly Interests: Education, Graduate Medical, Head and Neck Cancer, Mathematical Model, Models, Biologic, Neural Network Models, Salivary Gland Cancers, Statistical Models, Therapies, Combined Modality, Tumor Cell Lines, Tumor Immune Escape
  • Websites: Research Network Profile
  • Contact: apearson5@uchicago.edu
  • Graduate Programs: Cancer Biology, Genetics, Genomics & Systems Biology, UChicago Biosciences

The Pearson Lab integrates clinical expertise, mathematical modeling, high dimensional statistics, and basic tumor biology methods to investigate and propose new treatments for head and neck cancer.

University of Michigan
Ann Arbor, MI
Fellowship - Hematology/Oncology
2016

University of Michigan
Ann Arbor, MI
Postdoctoral Fellowship - Nor Lab (2013-2017)
2016

University of Michigan
Ann Arbor, MI
Residency - Internal Medicine
2012

University of Rochester
Rochester, NY
MD - Medicine
2010

University of Rochester
Rochester, NY
PhD - Statistics
2009

Cornell University
Ithaca, NY
BS - Biometry and Statistics
2002

Generative adversarial networks accurately reconstruct pan-cancer histology from pathologic, genomic, and radiographic latent features.
Generative adversarial networks accurately reconstruct pan-cancer histology from pathologic, genomic, and radiographic latent features. Sci Adv. 2024 Nov 15; 10(46):eadq0856.
PMID: 39546597

Artificial intelligence-based morphologic classification and molecular characterization of neuroblastic tumors from digital histopathology.
Artificial intelligence-based morphologic classification and molecular characterization of neuroblastic tumors from digital histopathology. NPJ Precis Oncol. 2024 Nov 08; 8(1):255.
PMID: 39511421

Developing a low-cost, open-source, locally manufactured workstation and computational pipeline for automated histopathology evaluation using deep learning.
Developing a low-cost, open-source, locally manufactured workstation and computational pipeline for automated histopathology evaluation using deep learning. EBioMedicine. 2024 Sep; 107:105276.
PMID: 39197222

Agent-Based Modeling of Virtual Tumors Reveals the Critical Influence of Microenvironmental Complexity on Immunotherapy Efficacy.
Agent-Based Modeling of Virtual Tumors Reveals the Critical Influence of Microenvironmental Complexity on Immunotherapy Efficacy. Cancers (Basel). 2024 Aug 23; 16(17).
PMID: 39272799

Applications of artificial intelligence to myeloproliferative neoplasms: a narrative review.
Applications of artificial intelligence to myeloproliferative neoplasms: a narrative review. Expert Rev Hematol. 2024 Oct; 17(10):669-677.
PMID: 39114884

Artificial Intelligence Applications in Oral Cancer and Oral Dysplasia.
Artificial Intelligence Applications in Oral Cancer and Oral Dysplasia. Tissue Eng Part A. 2024 Oct; 30(19-20):640-651.
PMID: 39041628

Carcinoma-associated mesenchymal stem cells promote ovarian cancer heterogeneity and metastasis through mitochondrial transfer.
Carcinoma-associated mesenchymal stem cells promote ovarian cancer heterogeneity and metastasis through mitochondrial transfer. Cell Rep. 2024 Aug 27; 43(8):114551.
PMID: 39067022

Neoadjuvant Nivolumab Plus Chemotherapy Followed By Response-Adaptive Therapy for HPV+ Oropharyngeal Cancer: OPTIMA II Phase 2 Open-Label Nonrandomized Controlled Trial.
Neoadjuvant Nivolumab Plus Chemotherapy Followed By Response-Adaptive Therapy for HPV+ Oropharyngeal Cancer: OPTIMA II Phase 2 Open-Label Nonrandomized Controlled Trial. JAMA Oncol. 2024 Jul 01; 10(7):923-931.
PMID: 38842838

Evaluation of large language models as a diagnostic aid for complex medical cases.
Evaluation of large language models as a diagnostic aid for complex medical cases. Front Med (Lausanne). 2024; 11:1380148.
PMID: 38966538

Development and validation of a clinical breast cancer tool for accurate prediction of recurrence.
Development and validation of a clinical breast cancer tool for accurate prediction of recurrence. NPJ Breast Cancer. 2024 Jun 15; 10(1):46.
PMID: 38879577

View All Publications

Mark Roth Award
University of Michigan
2015

Chief Fellow in Hematology/Oncology
University of Michigan
2014 - 2015

Information For Patients